Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy

First-line osimertinib may provide real-world clinical benefits for patients with advanced NSCLC with atypical EGFR mutations, with results suggesting greater benefit in those harboring compound EGFR mutations.

Authors

Institutions

Publication Details

Journal
Oncology and Therapy
Published
2025-11-09
DOI
https://doi.org/10.1007/s40487-025-00395-7
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy

Deborah B. Doroshow, Leslie Servidio, Yan Kwan Lau, Miranda Cooper et al.
Oncology and Therapy
Lung Cancer Treatments and Mutations
article

Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy

Deborah B. Doroshow, Leslie Servidio, Yan Kwan Lau, Miranda Cooper, Pritesh S. Karia, Jorge J. Nieva, Jacqulyne Robichaux, Xuejun Wang
article en

Abstract

First-line osimertinib may provide real-world clinical benefits for patients with advanced NSCLC with atypical EGFR mutations, with results suggesting greater benefit in those harboring compound EGFR mutations.

Oncology and TherapyVol. 14(1)
AstraZeneca (Netherlands) (NL), AstraZeneca (Singapore) (SG), AstraZeneca (Brazil) (BR), USC Norris Comprehensive Cancer Center (US), AstraZeneca (Japan) (JP), AstraZeneca (United States) (US), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 52%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy — Deborah B. Doroshow, Leslie Servidio, et al. · Oncology and Therapy (2025) | TGRS Research Map | TGRS